Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 20/20 | 0.65 |
| ▸ | ITGB2 | P05107 | 19/20 | 0.65 |
| ▸ | ICAM1 | P05362 | 19/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23176446 | 0.85 | ITGAL (0.48) | ITGALITGB2ICAM1 | |
| SCHEMBL13894114 | 0.85 | ITGAL (0.48) | ITGALITGB2ICAM1 | |
| SCHEMBL18867977 | 0.85 | ITGAL (0.49) | ITGALITGB2ICAM1 | |
| SCHEMBL17991461 | 0.84 | ITGAL (0.76) | ITGALITGB2ICAM1 | |
| SCHEMBL18868508 | 0.84 | ITGAL (0.46) | ITGALITGB2ICAM1 | |
| SCHEMBL23176604 | 0.84 | ITGAL (0.46) | ITGALITGB2ICAM1 | |
| SCHEMBL18868608 | 0.83 | ITGAL (0.45) | ITGALITGB2ICAM1 | |
| SCHEMBL13894065 | 0.83 | ITGAL (0.48) | ITGALITGB2ICAM1 | |
| SCHEMBL13813596 | 0.82 | ITGAL (0.47) | ITGALITGB2ICAM1 | |
| SCHEMBL13821870 | 0.82 | ITGAL (0.46) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232019-A1 | Compositions and Methods for Treatment of Eye Disorders | SARCODE BIOSCIENCE INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232019-A1 | Compositions and Methods for Treatment of Eye Disorders | SARCODE BIOSCIENCE INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-04-15 | — | — | US | disclosed |
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092542-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB2 8/4885ICAM1 1/4885 |
| US-20120232019-A1 | Compositions and Methods for Treatment of Eye Disorders | ICAM1, VCAM1, ITGAL | ITGAL 3/4885ITGB2 8/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.